Xindatai: SAL0145 Injection Approved to Conduct Clinical Trials for MASH Indication

Xinyitai Pharmaceuticals announcement: Recently, the company received a “Clinical Trial Approval Notice” that had been reviewed and approved by the National Medical Products Administration, confirming approval. It agrees that the company’s independently developed innovative drug, SAL0145 injection, will conduct clinical trials for the MASH indication.

View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin